Implantable Peripheral Nerve Stimulator for Treatment of Phantom Limb Pain
Implantable Peripheral Nerve Stimulator for Treatment of Phantom Limb Pain
批准号:
9932778
负责人:
Andrew Wilder
金额:
$198.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-30 至 2023-08-31
关键词:
AmputationAnimalsArchitectureCadaverCaliberChronicClinicalClinical ResearchComplexCoupledCustomDataDevelopmentDissociationEffectivenessElectric StimulationElectrodesEsthesiaEvaluationFamilyFeelingFiberFriendsImplantInstitutionIntuitionLimb structureMassageMechanicsMedical Device DesignsMedical centerMental DepressionNerveNerve BlockOperative Surgical ProceduresOpioidPainPain managementPerformancePeripheralPeripheral Nerve StimulationPeripheral NervesPhantom Limb PainPharmaceutical PreparationsPharmacological TreatmentPhasePhysiologic pulsePolymersPresbyterian ChurchPrintingProsthesisPruritusQuality of lifeReportingSafetySensorySiteSleepSpecificitySpine painSystemTechnologyTelemetryTestingTissuesTrainingWorkbasebiomaterial compatibilitychronic paindesensitizationdesigneffective therapyexperiencefallsfirst-in-humanflexibilityimplantable deviceimprovedlimb amputationneural stimulationneurotransmissionnon-opioid analgesicnovelpain sensationpreservationpressureprosthesis wearerprototyperelating to nervous systemresponserestorationsensory feedbacksensory inputside effectsignal processingsuccess
中文摘要
摘要
英文摘要
Abstract
Chronic phantom limb pain (PLP) has been reported to inflict as many as 80% of people with amputations. PLP is described
as feeling like burning, twisting, itching, or pressure in part of the missing limb. These painful sensations have a substantial
negative impact on quality of life; people who suffer PLP have high rates of depression, difficulty sleeping, regular absences
from work, dissociation with family/friends, and limited use of their prostheses. The use of medications to alleviate PLP is
only about 50% effective at managing pain; additionally, these medications have many undesirable side effects. Opioids
are a commonly prescribed pharmacological treatment, typically in conjuection with other medications. Non-pharmaceutical
approaches to PLP management have been reported with only 30% success rates. Implantable spinal pain stimulators have
demonstrated only limited effectiveness in managing PLP; the lack of specificity in targeting effected neural tissue
diminishes clinical benefit. In contrast, it has been demonstrated that stimulation used to restore sensation from the missing
limb is highly effective at eliminating PLP. Restoring these missing sensory inputs alters central processing of peripheral
sensation, thereby mitigating pain from the amputated limb. In addition, sensory restoration has the benefit of improving
stability and embodiment of a prosthesis.
In response to the need for improved treatment for PLP, Ripple proposes to develop an implantable neural stimulation
system to provide natural and intuitive sensation for prosthesis users. Ripple is experienced in printing custom, flexible, and
highly durable implantable electrode arrays. We are confident our nerve cuff technology meets all the requirements for a
sensory feedback system capable of providing consistent and controlled electrical stimulation. Coupled with Ripple’s
multichannel implantable stimulator, we believe this custom electrode array will offer substantial improvement over existing
options to treat PLP. We have developed this implantable multichannel stimulator with the capabilites of delivering arbitrary
waveform stimulation pulses on multiple independent channels, which are features required for sensory feedback
stimulation. As a system integrator on the DARPA HAPTIX project, we have already developed a prototype implantable
stimulator capable of restoring sensation from a missing limb via peripheral nerve stimulation.
In Phase I, we will finalize array architectures for evaluation in cadaver studies, complete integration of electrodes with our
implantable stimulator, conduct benchtop verification of electrical and mechanical performance in accelerated lifetime
testing, send implants out for third-party evaluation of system biocompatibility, and complete a 6-month GLP animal study
to validate safety and efficacy. At the end of Phase I, we will submit an IDE to the FDA for first-in-human testing of the
implantable system.
In Phase II, we will conduct a 5-subject clinical study to test the implantable stimulation system with the clinical team at
Presbyterian St. Luke’s Medical Center in Denver, CO. Dr. Giancarlo Barolat is a world expert in neurostimulation therapy
for chronic pain and Dr. David Hahn leads the Institution for Limb Preservation, an advanced center specializing in
amputations and complex limb surgeries. Each unilateral prosthesis user will be implanted for one year as we evaluate the
safety and efficacy of this implantable device to treat PLP.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金